Gilead Pushes PrEP Envelope As ViiV Explores Self-Administered, Long-Acting Drugs
The two companies were among those presenting data at CROI that highlighted the next frontiers of competition in the HIV space.
The two companies were among those presenting data at CROI that highlighted the next frontiers of competition in the HIV space.